A Prospective Observational Study for Comparative Evaluation of Combined Ipratropium Bromide-Levosalbutamol versus Levosalbutamol Monotherapy in the Management of Obstructive Pulmonary Diseases
Research Article
DOI:
https://doi.org/10.69613/jzdqk620Keywords:
Obstructive pulmonary disease, Ipratropium bromide, Levosalbutamol, Peak expiratory flow rate, Quality of lifeAbstract
This prospective observational study is conducted to evaluate the efficacy of combined ipratropium bromide-levosalbutamol therapy compared to levosalbutamol monotherapy in managing obstructive pulmonary diseases. The study was conducted at GSL General Hospital and Medical College, Rajamahendravaram, over six months from October 2023 to April 2024. Thirty-nine patients were enrolled, with 26 receiving combination therapy and 13 receiving monotherapy. Treatment outcomes were assessed using Peak Expiratory Flow Rate (PEFR), St George's Respiratory Questionnaire (SGRQ), and Cough Symptom Score (CSS). Initial PEFR values were ≤130 L/min for all patients. Post-treatment, both groups showed significant improvements in PEFR, with the combination therapy group showing a mean increase from 80.51 to 147.69 L/min. SGRQ scores improved significantly in both groups, with mean scores decreasing from 55.25 to 30.11. CSS evaluations demonstrated substantial improvements in both daytime and nighttime symptoms across both treatment groups. Statistical analysis using the Wilcoxon Matched Pairs test revealed significant within-group improvements for all parameters (p<0.0001). However, between-group comparisons showed no statistically significant differences in treatment outcomes. It can be concluded from this study that both combination therapy and monotherapy are equally effective in managing obstructive pulmonary diseases, suggesting that either treatment approach can be safely implemented based on individual patient needs.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Journal of Pharma Insights and Research

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.